Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | MMP2 | P08253 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17606328 | 1.00 | CA12 (0.31) | CA12CA1CA2MMP2CA9 | |
| SCHEMBL15816596 | 1.00 | CA12 (0.31) | CA12CA1CA2MMP2CA9 | |
| SCHEMBL30268847 | 1.00 | CA12 (0.31) | CA12CA1CA2MMP2CA9 | |
| SCHEMBL17605558 | 1.00 | CA12 (0.31) | CA12CA1CA2MMP2CA9 | |
| SCHEMBL17606329 | 1.00 | CA12 (0.31) | CA12CA1CA2MMP2CA9 | |
| SCHEMBL15816597 | 1.00 | CA12 (0.31) | CA12CA1CA2MMP2CA9 | |
| SCHEMBL30238647 | 0.96 | CA12 (0.34) | CA12CA1CA2MMP2CA9 | |
| SCHEMBL30268841 | 0.96 | CA12 (0.34) | CA12CA1CA2MMP2CA9 | |
| SCHEMBL15663044 | 0.96 | CA12 (0.34) | CA12CA1CA2MMP2CA9 | |
| SCHEMBL15663045 | 0.96 | CA12 (0.34) | CA12CA1CA2MMP2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3418280-B1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INT (DE) | 2023-07-12 | — | — | EP | disclosed |
| EP-3131902-B1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INT (DE) | 2019-06-12 | — | — | EP | disclosed |
| US-20190002465-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INT (DE) | 2019-01-03 | — | — | US | disclosed |
| US-20180022749-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INT (DE) | 2018-01-25 | — | — | US | disclosed |
| US-20180022749-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INT (DE) | 2018-01-25 | — | — | US | disclosed |
| US-9598415-B2 | Compounds as modulators of RORγ | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-03-21 | — | — | US | disclosed |
| US-9598415-B2 | Compounds as modulators of RORγ | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-03-21 | — | — | US | disclosed |
| US-20170008894-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INT (DE) | 2017-01-12 | — | — | US | disclosed |
| US-20170008894-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INT (DE) | 2017-01-12 | — | — | US | disclosed |
| US-20160075706-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INT (DE) | 2016-03-17 | — | — | US | disclosed |
| US-9242989-B2 | Compounds as modulators of RORγ | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-26 | — | — | US | disclosed |
| US-9242989-B2 | Compounds as modulators of RORγ | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-26 | — | — | US | disclosed |
| WO-2015160654-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-22 | — | — | WO | disclosed |
| US-20150291607-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-15 | — | — | US | disclosed |
| US-20150291607-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022749-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | RORB, RORC, RORA | CA12 1433/4885CA1 1772/4885CA2 2461/4885 |
| US-20170008894-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | RORB, RORC, RORA | CA12 1433/4885CA1 1772/4885CA2 2461/4885 |
| US-20150291607-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | RORB, RORC, RORA | CA12 1433/4885CA1 1772/4885CA2 2461/4885 |
| US-20190002465-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | RORB, RORC, RORA | CA12 1433/4885CA1 1772/4885CA2 2461/4885 |
| US-20160075706-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | RORB, RORC, RORA | CA12 1433/4885CA1 1772/4885CA2 2461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.